Raise closed, search for fresh raises on Seedstage

Portland, OR

Expanding commercial deployment of a device that enhances standard endoscopes with cost-effective ultrasound diagnostics.

• FDA cleared device: EndoSound Vision System enables advanced imaging without costly new equipment.
• Strong early adoption: Used in over 600 procedures with high clinical acceptance.
• Revenue in place: Combines capital sales with recurring revenue from single-use disposables.
• Market traction: Existing CMS reimbursement and growing U.S. and international demand.
• Massive market: Positioned within a $20.1B global GI diagnostics opportunity.

EndoSound is raising funds to support the commercial scaling of its FDA-cleared EndoSound Vision System, a novel device that upgrades standard endoscopes with advanced ultrasound capabilities. This technology enables Echo-EGD, a diagnostic approach that combines endoscopy and ultrasound imaging to detect serious gastrointestinal conditions at earlier stages. EndoSound’s system addresses key limitations of legacy EUS platforms, which are expensive, difficult to maintain, and limited in accessibility due to cost and complexity. By retrofitting existing scopes rather than requiring new, high-cost equipment, the company significantly reduces the financial barrier to entry, making advanced GI diagnostics viable in outpatient and rural care settings.

The capital from this raise will fund expanded sales and distribution in the U.S. and Latin America, increase production capacity for the system and disposables, and support further clinical validation and regulatory submissions. The company has already demonstrated market traction, performing over 600 procedures and securing partnerships with clinical sites, as well as CMS reimbursement for its disposables. With a revenue model based on system sales and recurring revenue from disposables, EndoSound is positioned for scalable and capital-efficient growth. Its market potential spans multiple clinical applications across a $20.1B global diagnostics landscape. This offering will help the company accelerate deployment, expand its commercial footprint, and further validate its approach to making high-quality GI imaging broadly accessible.

Company Info

EndoSound retrofits standard endoscopes with ultrasound imaging to enable scalable, cost-effective gastrointestinal diagnostics.

EndoSound develops and commercializes a diagnostic platform that enhances standard endoscopes with advanced ultrasound capabilities to improve gastrointestinal disease detection. The company’s FDA-cleared EndoSound Vision System retrofits existing GI endoscopes to perform Echo-EGD—combining video and ultrasound into a single view—enabling more accurate and minimally invasive diagnostics for conditions such as pancreatic and liver disease. This system is designed to be used in a variety of clinical settings including hospitals, ambulatory surgery centers, and rural clinics, and aims to reduce costs and improve access to high-quality diagnostics.

With a hybrid revenue model that includes a $40,000 system sale and $650 per-procedure disposable use, EndoSound provides a scalable solution with favorable reimbursement economics. The platform has already been used in over 600 clinical procedures with high acceptance rates and has been adopted in early markets in the U.S. and internationally. Supported by 10 awarded and 10 pending patents, EndoSound addresses a growing $20.1 billion global market for GI and echo-endoscopy diagnostics. The company has received FDA Breakthrough Device designation and aims to continue expanding its clinical reach and regulatory approvals to bring advanced imaging to underserved populations.